Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

169 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Microsatellite instability associated with durable complete response to PD-L1 inhibitor in head and neck squamous cell carcinoma.
Tardy MP, Di Mauro I, Ebran N, Refae S, Bozec A, Benezery K, Peyrade F, Guigay J, Sudaka-Bahadoran A, Badoual C, Pedeutour F, Saada-Bouzid E. Tardy MP, et al. Among authors: peyrade f. Oral Oncol. 2018 May;80:104-107. doi: 10.1016/j.oraloncology.2018.04.001. Epub 2018 Apr 7. Oral Oncol. 2018. PMID: 29631799 No abstract available.
Molecular genetics of head and neck squamous cell carcinoma.
Saada-Bouzid E, Peyrade F, Guigay J. Saada-Bouzid E, et al. Among authors: peyrade f. Curr Opin Oncol. 2019 May;31(3):131-137. doi: 10.1097/CCO.0000000000000536. Curr Opin Oncol. 2019. PMID: 30893149 Review.
Approach to the Patient with Recurrent/Metastatic Disease.
Guigay J, Sâada-Bouzid E, Peyrade F, Michel C. Guigay J, et al. Among authors: peyrade f. Curr Treat Options Oncol. 2019 Jun 25;20(8):65. doi: 10.1007/s11864-019-0664-z. Curr Treat Options Oncol. 2019. PMID: 31240480 Review.
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Guigay J, Aupérin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, Geoffrois L, Martin L, Capitain O, Cupissol D, Castanie H, Vansteene D, Schafhausen P, Johnson A, Even C, Sire C, Duplomb S, Evrard C, Delord JP, Laguerre B, Zanetta S, Chevassus-Clément C, Fraslin A, Louat F, Sinigaglia L, Keilholz U, Bourhis J, Mesia R; GORTEC; AIO; TTCC, and UniCancer Head and Neck groups. Guigay J, et al. Lancet Oncol. 2021 Apr;22(4):463-475. doi: 10.1016/S1470-2045(20)30755-5. Epub 2021 Mar 5. Lancet Oncol. 2021. PMID: 33684370 Clinical Trial.
Observational, prospective, phase 4 study in patients with first-line recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with cetuximab and platinum-based therapy: DIRECT.
Guigay J, Chamorey E, Lefebvre G, Rotarski M, Wagner JP, Blot E, Alfonsi M, Seronde A, Schulten J, Peyrade F, Le Tourneau C. Guigay J, et al. Among authors: peyrade f. Cancer Rep (Hoboken). 2022 Feb;5(2):e1467. doi: 10.1002/cnr2.1467. Epub 2021 Jun 22. Cancer Rep (Hoboken). 2022. PMID: 34156166 Free PMC article. Clinical Trial.
Induction chemotherapy-based larynx preservation program for locally advanced hypopharyngeal cancer: oncologic and functional outcomes and prognostic factors.
Bozec A, Benezery K, Ettaiche M, Chamorey E, Vandersteen C, Dassonville O, Poissonnet G, Riss JC, Hannoun-Lévi JM, Chand ME, Leysalle A, Saada E, Guigay J, Sudaka A, Demard F, Santini J, Peyrade F. Bozec A, et al. Among authors: peyrade f. Eur Arch Otorhinolaryngol. 2016 Oct;273(10):3299-306. doi: 10.1007/s00405-016-3919-3. Epub 2016 Feb 9. Eur Arch Otorhinolaryngol. 2016. PMID: 26858198
169 results